Foley Partner David Rosen was quoted in an article that appeared in FDA Week on June 24, 2010 titled “OIG, Stakeholders Urge FDA To Clamp Down On Foreign Clinical Trials.” Rosen discusses criticisms directed towards the Food and Drug Administration (FDA) by lawmakers and drug safety advocates for what they view as lackluster oversight of clinical trials conducted abroad. He states that data collected during pivotal trials is likely to come under scrutiny by the FDA, adding that the majority of companies are working hard to ensure that data generated outside the U.S. is of very high quality.
People
Related News
August 19, 2025
In the News
Gustavo Resendiz Featured in Q&A on Secondary Market Momentum – 'Investors want liquidity'
Foley & Lardner LLP partner Gustavo Resendiz is featured in the Crunchbase News Q&A, "Why Secondary Funds Still Can’t Keep Up With Investor Demand," lending insight into the accelerating investor momentum towards secondary transactions.
August 18, 2025
In the News
David Simon Coauthors Piece on Empowering Lawyers as Strategic Business Partners
Foley & Lardner LLP partner David Simon coauthored The Agenda article, "Turn Your Corporate Lawyer into a Strategic Weapon," published by Financial Times.
August 15, 2025
In the News
Gregory Husisian on Voluntary Disclosures to Customs – 'Importing has never been riskier'
Foley & Lardner LLP partner Gregory Husisian authored the SupplyChainBrain article, "Best Practices for Making Voluntary Disclosures to Customs," sharing insight on this vital strategy for companies looking to mitigate risk from U.S. Customs and Border Protection.